港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

勁方醫藥-B

32.260

-1.240-3.70%

成交量：108.40萬

成交額：3,501.69萬

市值：119.36億

市盈率：-4.60

高：34.240

開：32.980

低：31.040

收：33.500

52周最高：52.900

52周最低：19.600

股本：3.70億

香港流通股本：3.38億

量比：0.97

換手率：0.32%

股息：- -

股息率：- -

每股收益(LYR):-7.010

淨資產收益率：--

總資產收益率：-12.49%

市淨率：5.70

市盈率(LYR):-4.60

市銷率: 79.35

資料載入中...

總覽公司新聞資訊公告

異動解讀 | 核心產品獲突破性療法認定，勁方醫藥-B盤中大漲5.48%

港股勁方醫藥-B盤中升逾22%

每日经济新闻

勁方醫藥-B3月股份變動月報：股本維持穩定

港股異動 | 勁方醫藥-B(02595)早盤升逾5% GFH375獲得第二項突破性療法認定

勁方醫藥-B(02595)：GFH375獲得第二項突破性療法認定

勁方醫藥-B旗下Gfh375獲國家藥監局突破性治療藥物認定

異動解讀 | 勁方醫藥-B獲Wellington Management增持，盤中大漲5.14%

Wellington Management Group LLP增持勁方醫藥-B(02595)約31.82萬股每股均價約30.88港元

《大行》里昂升勁方醫藥(02595.HK)目標價至61.9元評級「跑贏大市」

阿斯达克财经

勁方醫藥－Ｂ(02595)出現大手買入66.16萬股，成交價$30.1，涉資1.991千萬

阿斯达克财经

異動解讀 | 勁方醫藥-B盤中大漲5.34%，年度業績增長及核心藥物III期進展成催化劑

勁方醫藥-B(02595)：黃美鳳獲委任為聯席公司秘書

勁方醫藥-B(02595)發布年度業績淨虧損17.95億元按年擴大164.82%

Wellington Management Group LLP增持勁方醫藥-B(02595)382.34萬股每股作價25.5港元

勁方醫藥(02595.HK)將於AACR年會展示三款產品臨床前研究數據

阿斯达克财经

勁方醫藥-B(02595)將於2026年AACR年會上展示三款RAS通路相關的大、小分子靶向藥臨床前研究數據

勁方醫藥(02595)午後漲22.54% 公司宣佈三款新藥入選AACR壁報環節

勁方醫藥－Ｂ(02595)股價上升9.538%，現價港幣$28.48

阿斯达克财经

Wellington Management Group LLP增持勁方醫藥-B(02595)252.42萬股每股作價約27.26港元

勁方醫藥－Ｂ(02595)股價上升5.213%，現價港幣$28.66

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02595/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02595","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"勁方醫藥-B","latestPrice":32.26,"timestamp":1779782902006,"preClose":33.5,"halted":0,"volume":1083955,"delay":0,"changeRate":-0.03701492537313439,"floatShares":338000000,"shares":370000000,"eps":-7.009521417488205,"marketStatus":"未開盤","change":-1.24,"latestTime":"05-26 16:08:22","open":32.98,"high":34.24,"low":31.04,"amount":35016880,"amplitude":0.095522,"askPrice":32.26,"askSize":200,"bidPrice":32.14,"bidSize":4200,"shortable":3,"etf":0,"ttmEps":-6.1942459445480615,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1779845400000},"marketStatusCode":0,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":33.5,"openAndCloseTimeList":[[1779759000000,1779768000000],[1779771600000,1779782400000]],"volumeRatio":0.967063,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","floatShares":338000000,"roa":"-12.49%","roe":"--","lyrEps":-7.009521,"volumeRatio":0.967063,"shares":370000000,"dividePrice":0,"high":34.24,"amplitude":0.095522,"preClose":33.5,"low":31.04,"week52Low":19.6,"pbRate":"5.70","psRate":"79.35","week52High":52.9,"institutionHeld":0,"latestPrice":32.26,"committee":0.909091,"eps":-7.009521417488205,"divideRate":0,"volume":1083955,"delay":0,"ttmEps":-6.1942459445480615,"open":32.98,"prevYearClose":23.78,"prevWeekClose":33.5,"prevMonthClose":43.14,"prevQuarterClose":33.42,"fiveDayClose":34.44,"twentyDayClose":49.46,"sixtyDayClose":28.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02595\",params:#limit:5,,,undefined,":[{"date":"2026-03-24","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774315800000,"name":null,"time":"","dateTimestamp":1774281600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02595\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02595\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1776268800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02595\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02595","date":"2026-05-22","current":-5.209201,"percent":0.919753,"low":-19.62221,"twenty":-11.098455,"median":-10.138144,"eighty":-8.800358,"high":-5.69787,"avg":-10.419693,"sd":2.620978,"marketCap":12407282105},"quantilePoints":[{"date":"2025-09-19","current":-19.62221,"twenty":-19.62221,"median":-19.62221,"eighty":-19.62221,"marketCap":14538840523},{"date":"2025-09-26","current":-17.850791,"twenty":-18.989349,"median":-18.569255,"eighty":-18.336187,"marketCap":13192012066},{"date":"2025-10-03","current":-19.06699,"twenty":-19.162092,"median":-18.845312,"eighty":-18.417026,"marketCap":14124431767},{"date":"2025-10-10","current":-11.809112,"twenty":-19.045684,"median":-18.645404,"eighty":-16.087956,"marketCap":11948785798},{"date":"2025-10-17","current":-10.861917,"twenty":-19.006201,"median":-18.336187,"eighty":-11.374297,"marketCap":10981832034},{"date":"2025-10-24","current":-9.567304,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"marketCap":9676444452},{"date":"2025-10-31","current":-9.989391,"twenty":-18.681528,"median":-11.762498,"eighty":-10.081819,"marketCap":10118416331},{"date":"2025-11-07","current":-9.878556,"twenty":-18.646705,"median":-10.725216,"eighty":-9.89625,"marketCap":9999899010},{"date":"2025-11-14","current":-11.674836,"twenty":-18.558233,"median":-10.712517,"eighty":-9.936062,"marketCap":11851732160},{"date":"2025-11-21","current":-10.329745,"twenty":-18.396816,"median":-10.725216,"eighty":-10.005136,"marketCap":10481375629},{"date":"2025-11-28","current":-10.423287,"twenty":-18.142029,"median":-10.678396,"eighty":-10.044836,"marketCap":10614707615},{"date":"2025-12-05","current":-10.100425,"twenty":-16.087956,"median":-10.631034,"eighty":-10.044836,"marketCap":10303599646},{"date":"2025-12-12","current":-10.212238,"twenty":-13.008301,"median":-10.584309,"eighty":-10.020393,"marketCap":10436931633},{"date":"2025-12-19","current":-9.790532,"twenty":-12.136764,"median":-10.450758,"eighty":-9.957409,"marketCap":10029528340},{"date":"2025-12-24","current":-8.945585,"twenty":-11.809112,"median":-10.416014,"eighty":-9.900509,"marketCap":9192499756},{"date":"2026-01-02","current":-8.020182,"twenty":-11.73453,"median":-10.320373,"eighty":-9.861601,"marketCap":8273990514},{"date":"2026-01-09","current":-11.588563,"twenty":-11.683046,"median":-10.309663,"eighty":-9.776189,"marketCap":11985064146},{"date":"2026-01-16","current":-11.693807,"twenty":-11.67863,"median":-10.369243,"eighty":-9.793132,"marketCap":12133210798},{"date":"2026-01-23","current":-10.361602,"twenty":-11.605818,"median":-10.329745,"eighty":-9.783265,"marketCap":10740632270},{"date":"2026-01-30","current":-10.919089,"twenty":-11.483053,"median":-10.385171,"eighty":-9.793132,"marketCap":11370255541},{"date":"2026-02-06","current":-11.146899,"twenty":-11.598147,"median":-10.450758,"eighty":-9.8258,"marketCap":11636919514},{"date":"2026-02-13","current":-10.659945,"twenty":-11.483053,"median":-10.58187,"eighty":-9.869606,"marketCap":11192479558},{"date":"2026-02-20","current":-10.145441,"twenty":-11.446311,"median":-10.573435,"eighty":-9.881527,"marketCap":10636929613},{"date":"2026-02-27","current":-9.574146,"twenty":-11.38719,"median":-10.509847,"eighty":-9.836956,"marketCap":10148045662},{"date":"2026-03-06","current":-8.841756,"twenty":-11.29428,"median":-10.416014,"eighty":-9.744297,"marketCap":9296202413},{"date":"2026-03-13","current":-10.316011,"twenty":-11.38719,"median":-10.450758,"eighty":-9.761464,"marketCap":10896186254},{"date":"2026-03-20","current":-10.186272,"twenty":-11.29428,"median":-10.385171,"eighty":-9.744297,"marketCap":10718410272},{"date":"2026-03-27","current":-5.945762,"twenty":-11.270982,"median":-10.329745,"eighty":-9.723416,"marketCap":12081359470},{"date":"2026-04-02","current":-6.621163,"twenty":-11.205287,"median":-10.312136,"eighty":-9.574146,"marketCap":13518381995},{"date":"2026-04-10","current":-7.067323,"twenty":-11.18954,"median":-10.310332,"eighty":-9.547859,"marketCap":14540593893},{"date":"2026-04-17","current":-8.194366,"twenty":-11.170082,"median":-10.271344,"eighty":-9.114302,"marketCap":16866496330},{"date":"2026-04-24","current":-11.736244,"twenty":-11.170082,"median":-10.248784,"eighty":-8.950161,"marketCap":18318333519},{"date":"2026-04-30","current":-10.233962,"twenty":-11.173069,"median":-10.230093,"eighty":-8.995356,"marketCap":15977616418},{"date":"2026-05-08","current":-9.881779,"twenty":-11.158327,"median":-10.186272,"eighty":-9.095725,"marketCap":15481325134},{"date":"2026-05-15","current":-8.422278,"twenty":-11.148553,"median":-10.161068,"eighty":-8.948635,"marketCap":13229496023},{"date":"2026-05-22","current":-7.916926,"twenty":-11.098455,"median":-10.138144,"eighty":-8.800358,"marketCap":12407282105}],"updateTime":1779809869884},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02595\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1115933132","title":"異動解讀 | 核心產品獲突破性療法認定，勁方醫藥-B盤中大漲5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115933132","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115933132?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 09:39","pubTimestamp":1776217187,"startTime":"0","endTime":"0","summary":"劲方医药-B今日盘中大涨5.48%，引起了市场的广泛关注。消息面上，公司近日宣布其自主研发的口服高选择性KRAS G12D抑制剂GFH375被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，拟用于单药治疗至少接受过一种系统性治疗的KRAS G12D突变型转移性患者，系国内首个获该适应症BTD认定的KRAS G12D抑制剂单药治疗方案。KRAS突变在胰腺癌中发生率高达90%，而该癌种五年生存率低于10%，临床需求迫切。公司计划于今年学术会议中公布GFH375在不同适应症试验中的最新数据，市场对该管线商业化前景的关注持续升温。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627949947","title":"港股勁方醫藥-B盤中升逾22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627949947","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627949947?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 12:01","pubTimestamp":1776139262,"startTime":"0","endTime":"0","summary":"【港股劲方医药-B盘中涨超22%】4月14日，劲方医药-B(02595.HK)盘中涨超22%，截至发稿涨14.37%，报44.88港元，成交额1.94亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704180475.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704180475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","02595","VXUS","BK1515","BK4585","159938","09939","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145482467","title":"勁方醫藥-B3月股份變動月報：股本維持穩定","url":"https://stock-news.laohu8.com/highlight/detail?id=1145482467","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145482467?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 17:11","pubTimestamp":1775725900,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司（下称“劲方医药-B”）于2026年4月9日发布截至2026年3月31日的股份变动月报。公告显示，公司本月内未新增发行、未进行股份购回或注销，各项股本数据保持不变。\n根据公告，截至3月31日，公司已发行H股338,029,020股，未上市股份32,337,610股，合计370,366,630股，所有股份的每股面值为人民币0.1元，总股本面值为人民币37,036,663元，与上月保持一致。报告期内，公司无新增股份期权或股权激励计划相关活动，也无购回及注销股份情况。\n公司同时确认已遵守香港联合交易所有限公司相关上市规则及法律规定。该公告由公司联席公司秘书张巍签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626971565","title":"港股異動 | 勁方醫藥-B(02595)早盤升逾5% GFH375獲得第二項突破性療法認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2626971565","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626971565?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 09:34","pubTimestamp":1775698443,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B早盘涨超5%，截至发稿，涨4.55%，报37.2港元，成交额553.09万港元。消息面上，劲方医药发布公告，口服KRAS G12D 抑制剂GFH375已被国家药品监督管理局药品审评中心纳入突破性疗法认定名单，拟用于单药治疗至少接受过一种系统性治疗的KRAS G12D突变型转移性胰腺癌患者。GFH375/VS-7375的海外临床研究由劲方合作伙伴Verastem Oncology于去年在美国启动，VS-7375已获得美国FDA快速通道资格认定治疗一线及后线KRAS G12D突变型胰腺导管腺癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4585","159938","09939","BK1515","02595","BK1161","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626996975","title":"勁方醫藥-B(02595)：GFH375獲得第二項突破性療法認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2626996975","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626996975?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 08:09","pubTimestamp":1775693389,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，口服KRAS G12D 抑制剂GFH375已被国家药品监督管理局药品审评中心纳入突破性疗法认定名单，拟用于单药治疗至少接受过一种系统性治疗的KRAS G12D突变型转移性胰腺癌患者。GFH375/VS-7375 的海外临床研究由劲方合作伙伴Verastem Oncology于2025年在美国启动，VS-7375已获得美国FDA快速通道资格认定治疗一线及后线KRAS G12D突变型胰腺导管腺癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02595","BK1515","159938","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142131271","title":"勁方醫藥-B旗下Gfh375獲國家藥監局突破性治療藥物認定","url":"https://stock-news.laohu8.com/highlight/detail?id=1142131271","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142131271?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 08:02","pubTimestamp":1775692936,"startTime":"0","endTime":"0","summary":"劲方医药（上海）有限公司（以下简称“劲方医药-B”）研发的创新药物Gfh375，近日正式获得中国国家药品监督管理局（NMPA）授予的突破性治疗药物认定。\n突破性治疗药物认定旨在加速具有突出临床价值的创新药研发与审评进程。Gfh375此次获得认定，标志着其在相关疾病治疗领域展现出显著的临床潜力。\n该认定将有助于劲方医药-B加快推进Gfh375的后续临床开发、申报与上市进程，为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172889689","title":"異動解讀 | 勁方醫藥-B獲Wellington Management增持，盤中大漲5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172889689","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172889689?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 10:10","pubTimestamp":1774923054,"startTime":"0","endTime":"0","summary":"劲方医药-B今日盘中大涨5.14%，引起了市场的广泛关注。消息面上，劲方医药-B获得Wellington Management Group LLP增持约31.82万股，总金额约为982.60万港元，增持后持股比例达到7.02%。机构投资者的增持行为通常被视为对公司前景的积极信号，增强了市场信心。Wellington Management Group LLP作为知名投资机构，其增持动作可能反映了对劲方医药-B长期价值的认可，从而推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314171","title":"Wellington Management Group LLP增持勁方醫藥-B(02595)約31.82萬股 每股均價約30.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314171","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314171?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 19:25","pubTimestamp":1774869941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，3月26日，Wellington Management Group LLP增持劲方医药-B(02595)31.8247万股，每股均价30.8754港元，总金额约为982.60万港元。增持后最新持股数目约为2374.17万股，持股比例为7.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02595","159938","BK1574","EWH","BK1515","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622221884","title":"《大行》里昂升勁方醫藥(02595.HK)目標價至61.9元 評級「跑贏大市」","url":"https://stock-news.laohu8.com/highlight/detail?id=2622221884","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622221884?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 10:16","pubTimestamp":1774491360,"startTime":"0","endTime":"0","summary":"里昂发表研究报告，劲方医药-B(02595.HK) 去年收入按年升24.4%及净亏损17.95亿元人民币，均优于市场预期。G12D GFH375已进入胰脏癌注册试验阶段，而pan-RAS GFH276有望成为劲方医药的长期增长动力。GFH276的I期剂量递增试验中已观察到积极的安全性讯号。该行指，将公司今年和明年盈利预测上调4%及5.3%，其目标价由60.8元上调至61.9元，维持其评级为“跑赢大市”。(ca/da)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-25 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250925155657502_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250925155657502_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512675/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512675/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["159938","02595","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622043117","title":"勁方醫藥－Ｂ(02595)出現大手買入66.16萬股，成交價$30.1，涉資1.991千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043117","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622043117?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 10:25","pubTimestamp":1774405500,"startTime":"0","endTime":"0","summary":"[大手成交]劲方医药－Ｂ(02595)在上午10:25出现大手买入，成交量为66.16万，成交价为港币$30.1，涉资1.991千万。至目前为止，股价升5.907%，今日最高价为$30.12，而最低价为$27.52，总成交量为220.902万股，总成交金额港币$6.55千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603255375/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603255375/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","09939","BK1574","02595","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122554050","title":"異動解讀 | 勁方醫藥-B盤中大漲5.34%，年度業績增長及核心藥物III期進展成催化劑","url":"https://stock-news.laohu8.com/highlight/detail?id=1122554050","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122554050?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 10:01","pubTimestamp":1774404060,"startTime":"0","endTime":"0","summary":"劲方医药-B今日盘中大涨5.34%，引起了市场的广泛关注。消息面上，公司发布了截至2025年12月31日止年度的年度业绩。公司收入达到1.3亿元人民币，同比增长约24.5%，增长主要得益于与Verastem就核心候选药物GFH375达成的合作及对外授权安排。其核心产品GFH375作为全球首个进入III期注册性临床试验的口服KRAS G12D抑制剂，已获得美国食品药品监督管理局的快速通道资格。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622014592","title":"勁方醫藥-B(02595)：黃美鳳獲委任為聯席公司秘書","url":"https://stock-news.laohu8.com/highlight/detail?id=2622014592","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622014592?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 07:52","pubTimestamp":1774396324,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，吴东澄因其专业事务重新安排及更深入参与客户业务及策略管理，已提呈辞任联席公司秘书、授权代表及法律程序文件代理人，自2026年3月24日起生效。黄美凤已获委任为联席公司秘书、授权代表及法律程序文件代理人，自2026年3月24日起生效。张巍将继续担任公司另一名联席公司秘书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02595","BK1515","BK1161","159938","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622145900","title":"勁方醫藥-B(02595)發布年度業績 淨虧損17.95億元 按年擴大164.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622145900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622145900?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 07:50","pubTimestamp":1774396243,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布截至2025年12月31日止年度业绩，收入人民币1.3亿元，同比增长24.42%;研发成本2.82亿元，同比减少15.01%;净亏损17.95亿元，同比扩大164.82%。公司历年来达成多个国内外授权交易，营业收入保持稳健。2025年度营业收入超过1.3亿元人民币、同比增幅近25%。此外公司现金流储备充足，截至2025年底现金及银行结余超过20亿元人民币。同时本公司是唯一一家在上市时拥有已商业化的1类创新药并产生对外授权收入的上市规则第18A章上市公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1515","02595","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621932770","title":"Wellington Management Group LLP增持勁方醫藥-B(02595)382.34萬股 每股作價25.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621932770","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621932770?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 19:07","pubTimestamp":1774264076,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，3月19日，Wellington Management Group LLP增持劲方医药-B(02595)382.34万股，每股作价25.5港元，总金额为9749.67万港元。增持后最新持股数目约为2159.22万股，持股比例为6.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159938","BK1515","02595","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621716099","title":"勁方醫藥(02595.HK)將於AACR年會展示三款產品臨床前研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2621716099","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621716099?lang=zh_tw&edition=fundamental","pubTime":"2026-03-22 15:26","pubTimestamp":1774164360,"startTime":"0","endTime":"0","summary":"劲方医药－Ｂ(02595.HK) 公布，公司将于2026年AACR年会壁报环节展示GFH276(非降解性分子胶)、GFS784(新型偶联药物，连接功能性抗体及机制协同性靶向药载荷)、GFH603(类分子胶共价变构激活剂)三款产品的临床前研究数据。本届AACR年会将于4月17日至22日日在美国圣地亚哥举行，公司参会壁报将分别于4月19日及21日展示。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-20 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250925155657502_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250925155657502_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511163/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511163/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02595","159938","BK1515","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620731689","title":"勁方醫藥-B(02595)將於2026年AACR年會上展示三款RAS通路相關的大、小分子靶向藥臨床前研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2620731689","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620731689?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 21:33","pubTimestamp":1774013615,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，公司将于2026年AACR年会壁报环节展示GFH276(非降解性分子胶)、GFS784(新型偶联药物，连接功能性抗体及机制协同性靶向药载荷)、GFH603(类分子胶共价变构激活剂)三款产品的临床前研究数据。公司RAS疗法矩阵聚焦多种选择性和泛RAS抑制剂，亦持续关注RAS通路重要共突变的潜在靶点;该矩阵包含多元分子形态、多机制RAS通路相关的大、小分子靶向药。届AACR年会将于2026年4月17日至22日在美国圣地亚哥举行，公司参会壁报将分别于4月19日和4月21日展示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416899.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09939","BK1574","02595","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620713202","title":"勁方醫藥(02595)午後漲22.54% 公司宣佈三款新藥入選AACR壁報環節","url":"https://stock-news.laohu8.com/highlight/detail?id=2620713202","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620713202?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 13:36","pubTimestamp":1773984997,"startTime":"0","endTime":"0","summary":"金吾财讯 | 劲方医药 午后大幅拉升，截至发稿，报31.86港元，涨22.54%，成交额1.49亿港元。消息面上，据劲方医药官微消息，公司宣布其管线中三款新药的临床前研究成果入选2026年美国癌症研究协会壁报环节，今年AACR年会将于2026年4月17日至22日在美国圣地亚哥举行。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","09939","02595","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620206058","title":"勁方醫藥－Ｂ(02595)股價上升9.538%，現價港幣$28.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2620206058","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620206058?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 10:35","pubTimestamp":1773974100,"startTime":"0","endTime":"0","summary":"[上升股]劲方医药－Ｂ(02595) 股价在上午10:35比前收市价上升9.538%，现股价为港币$28.48。至目前为止，今日最高价为$28.48，而最低价为$26.04。总成交量为82.04万股，总成交金额为港币$2.268千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2603201532/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2603201532/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02595","BK1515","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620247374","title":"Wellington Management Group LLP增持勁方醫藥-B(02595)252.42萬股 每股作價約27.26港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247374","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247374?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 19:53","pubTimestamp":1773921202,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，3月17日，Wellington Management Group LLP增持劲方医药-B(02595)252.42万股，每股作价27.259港元，总金额约为6880.72万港元。增持后最新持股数目约为1776.94万股，持股比例为5.26%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1161","02595","09939","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620831892","title":"勁方醫藥－Ｂ(02595)股價上升5.213%，現價港幣$28.66","url":"https://stock-news.laohu8.com/highlight/detail?id=2620831892","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620831892?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 10:35","pubTimestamp":1773801300,"startTime":"0","endTime":"0","summary":"[上升股]劲方医药－Ｂ(02595) 股价在上午10:35比前收市价上升5.213%，现股价为港币$28.66。至目前为止，今日最高价为$28.66，而最低价为$27.36。总成交量为284.06万股，总成交金额为港币$7.77千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260318739/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260318739/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","159938","BK1515","02595","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":105,"code":"91000000","status":"200"}]}}